Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.64 |
| ▸ | BRAF | P15056 | 4/20 | 0.64 |
| ▸ | RAF1 | P04049 | 11/20 | 0.61 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.61 |
| ▸ | CDK8 | P49336 | 2/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.61 |
| ▸ | KIT | P10721 | 2/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.61 |
| ▸ | FLT3 | P36888 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | PLK4 | O00444 | 1/20 | 0.61 |
| ▸ | CIT | O14578 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | MUSK | O15146 | 1/20 | 0.61 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.61 |
| ▸ | MLNR | O43193 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13945942 | 0.92 | KDR (0.65) | KDRBRAFRAF1MAPK3CDK8 | |
| SCHEMBL4211620 | 0.91 | RAF1 (0.75) | KDRBRAFRAF1MAPK3CDK8 | |
| SCHEMBL4201606 | 0.90 | KDR (0.63) | KDRBRAFRAF1MAPK3CDK8 | |
| SCHEMBL13946091 | 0.90 | BRAF (0.56) | KDRBRAFRAF1MAPK3CDK8 | |
| SCHEMBL13945963 | 0.90 | KDR (0.74) | KDRBRAFRAF1MAPK3CDK8 | |
| SCHEMBL13946029 | 0.88 | KMO (0.52) | KDRBRAFRAF1MAPK3CDK8 | |
| SCHEMBL13946014 | 0.87 | KDR (0.48) | KDRBRAFRAF1MAPK3CDK8 | |
| SCHEMBL13945992 | 0.86 | KDR (0.57) | KDRBRAFRAF1MAPK3CDK8 | |
| SCHEMBL4205631 | 0.86 | HDAC3 (0.63) | KDRBRAFRAF1MAPK3CDK8 | |
| SCHEMBL4209263 | 0.86 | RAF1 (0.82) | KDRBRAFRAF1MAPK3CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | CYP11B2, NOS2, HMOX2 | KDR 1151/4885BRAF 3443/4885RAF1 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.